X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, EffRx will grant Radius an exclusive, royalty bearing license to Binosto (alendronate sodium), an effervescent tablet for oral solution indicated for osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis, in the US.
Lead Product(s): Alendronate Sodium
Therapeutic Area: Musculoskeletal Product Name: Binosto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Radius Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 19, 2023
Details:
Through the acquisition, Abiogen gets Effrx's Binosto (alendronate sodium), an effervescent tablet for the treatment of osteoporosis. It will allow Abiogen to continue developing on Effrx's bisphosphonates family of molecules that in the area of osteoarticular metabolism.
Lead Product(s): Alendronate Sodium
Therapeutic Area: Musculoskeletal Product Name: Binosto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abiogen Pharma S.p.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 29, 2023
Details:
Efmody® is a modified-release preparation of hydrocortisone that has been specifically designed for the treatment of patients with CAH, a rare condition caused by a genetic deficiency of adrenal enzymes.
Lead Product(s): Hydrocortisone
Therapeutic Area: Genetic Disease Product Name: Efmody
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Diurnal Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
